Artiva says AB-101 plus rituximab posts 71% ACR50 response in refractory RA study

• Artiva Biotherapeutics flagged new clinical data for its AB-101 allogeneic NK-cell therapy with rituximab, scheduled for presentation at the EULAR 2026 Congress in London on June 3–6.
• The late-breaking oral presentation is set to show that the regimen produced strong clinical responses in rheumatologic diseases, described as comparable to outcomes reported with autologous CAR T-cell therapy.
• Additional EULAR presentations are expected to highlight durable benefit in severe rheumatoid arthritis, an initial experience in severe Sjögren disease, deep B-cell depletion, and a safety profile characterized as favorable in immune-mediated diseases.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Artiva Biotherapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202605191605PRIMZONEFULLFEED9723274) on May 19, 2026, and is solely responsible for the information contained therein.